hydroxychloroquine has been researched along with Nephrosis, Lipoid in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Nephrosis, Lipoid: A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, a few cases of minimal change glomerulopathy have been reported in association with systemic lupus erythematosus (SLE)." | 1.37 | A case of minimal change disease treated successfully with mycophenolate mofetil in a patient with systemic lupus erythematosus. ( Hong, YH; Jung, YW; Kim, HJ; Lee, CK; Oh, MJ; Yun, DY, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, YH | 1 |
| Yun, DY | 1 |
| Jung, YW | 1 |
| Oh, MJ | 1 |
| Kim, HJ | 1 |
| Lee, CK | 1 |
| Shahane, A | 1 |
| Khasnis, A | 1 |
| Gota, C | 1 |
2 other studies available for hydroxychloroquine and Nephrosis, Lipoid
| Article | Year |
|---|---|
A case of minimal change disease treated successfully with mycophenolate mofetil in a patient with systemic lupus erythematosus.
Topics: Antirheumatic Agents; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; | 2011 |
Rituximab-responsive nephrotic syndrome due to minimal change disease in systemic lupus erythematosus.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Diuretics; Drug Therapy, C | 2012 |